126 related articles for article (PubMed ID: 11362791)
1. Use and access to viral load measure assays: the need for validation.
Agosto M
Update Natl Minor AIDS Counc; 1995; ():7-8. PubMed ID: 11362791
[TBL] [Abstract][Full Text] [Related]
2. Viral phenotype and genotype as markers in clinical trials.
Katzenstein DA
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S25-34. PubMed ID: 7552510
[TBL] [Abstract][Full Text] [Related]
3. Viral load testing.
Sax P; Flory J
AIDS Clin Care; 1996 Apr; 8(4):31-2. PubMed ID: 11363258
[TBL] [Abstract][Full Text] [Related]
4. HIV surrogate markers: new virologic and immunologic indicators.
MacDougall DS
J Int Assoc Physicians AIDS Care; 1997 Mar; 3(3):15-7. PubMed ID: 11364123
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
6. Volunteers needed for study of HIV viral load test.
Oncology (Williston Park); 1996 Apr; 10(4):449-50. PubMed ID: 8723276
[No Abstract] [Full Text] [Related]
7. Therapeutic options or antiretroviral anarchy?
Mascolini M
J Int Assoc Physicians AIDS Care; 1999 Jan; 5(1):10-30. PubMed ID: 11366158
[TBL] [Abstract][Full Text] [Related]
8. [Quantification of T CD4+ lymphocytes and viral RNA in patients with HIV/AIDS].
Romero-Valdovinos M; Vázquez-Campuzano R; Hirota C; Torres M; González F; Correa D; Flisser A
Gac Med Mex; 2001; 137(5):501-4. PubMed ID: 11692820
[TBL] [Abstract][Full Text] [Related]
9. Viral-load testing may lower high cost of therapy.
AIDS Alert; 1996 Sep; 11(9):100-1. PubMed ID: 11363721
[TBL] [Abstract][Full Text] [Related]
10. The role of phenotyping and replication capacity in anti-HIV therapeutics.
Baliga CS; Sutton RE
Curr Opin Mol Ther; 2004 Jun; 6(3):308-17. PubMed ID: 15264434
[TBL] [Abstract][Full Text] [Related]
11. Closing the circle on HIV--or not.
Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Oct; 1(9):10-4, 17-29 contd. PubMed ID: 11362964
[TBL] [Abstract][Full Text] [Related]
12. Protease inhibitors: implications for HIV research and treatment.
Churchill SA
J Int Assoc Physicians AIDS Care; 1996 Jan; 2(1):13-8. PubMed ID: 11363325
[TBL] [Abstract][Full Text] [Related]
13. New study on viral load.
Posit Aware; 1996; 7(1):5. PubMed ID: 11363123
[TBL] [Abstract][Full Text] [Related]
14. An FDA-ok'd viral load test? The wait may be nearly over. Food and Drug Administration.
Mascolini M
J Int Assoc Physicians AIDS Care; 1996 Jan; 2(1):6-9. PubMed ID: 11363333
[TBL] [Abstract][Full Text] [Related]
15. Viral load: new confirmation from major delavirdine studies.
James JS
AIDS Treat News; 1996 Jan; (no 239):2-3. PubMed ID: 11363084
[TBL] [Abstract][Full Text] [Related]
16. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
17. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
Narciso P; Lazzarin A
Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
[TBL] [Abstract][Full Text] [Related]
18. AIDS pathogenesis: from models to viral dynamics in patients.
Nowak MA
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S1-5. PubMed ID: 8595501
[TBL] [Abstract][Full Text] [Related]
19. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
20. Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection.
Torti C; Barnes E; Quiros-Roldan E; Puoti M; Carosi G; Klenerman P
Antivir Ther; 2004 Feb; 9(1):139-42. PubMed ID: 15040546
[No Abstract] [Full Text] [Related]
[Next] [New Search]
